PCR58 Comparing Adherence in Patients with Type 2 Diabetes Initiating Glucagon-like Peptide-1 Receptor Agonists or Sodium-Glucose Cotransporter-2 Inhibitors

Non-adherence to antidiabetic medications is associated with worse clinical outcomes including poorer hemoglobin A1c (HbA1c). Both sodium-glucose cotransporter 2 (SGLT2I) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate clinical benefits in type 2 diabetes (T2DM) patients with an increased risk for cardiovascular disease. However, differences in route of administration and side effect profile may affect adherence. Therefore, the objective of this study is to evaluate and compare medication adherence among new adult users of SGLT2I and GLP-1 agonists.